Filing Flows › 8-K events › GeoVax Labs
GeoVax Labs: departure or appointment of directors and officers
Form 8-K filed Nov 6, 2026 · items 5.02
What the filing says
(b) Termination of President and Chief Executive Officer Dodd was terminated as President and Chief Executive Officer of the GeoVax Labs, Inc. (the “ Company ”), effective immediately.
Read the filing on SEC EDGAR →
What usually followsAcross 39,174 8-Ks reporting Item 5.02 (directors and officers: departures, appointments, pay) in our universe, the stock's median move the next session was −0.1% (typical size ±1.4%, up 48% of the time); over the following 21 sessions, +0.7%. Every item ranked →
What this kind of filing means
Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.
GeoVax Labs at a glance
GeoVax Labs, Q2 2025: revenue $852K (+184% year over year), operating margin -635.8%. The chart follows the revenue to costs, profit and cash.
GeoVax Labs: every quarter, Q/Q and Y/Y, holders and guidance →
GeoVax Labs’s other material 8-Ks
- Oct 27, 2026 — FDA decisions GeoVax Enters into $1 Million Revolving Loan Agreement
Other recent ceo changes
- CapForce Nov 6, 2026
- Federal Home Loan Bank of New York Nov 6, 2026
- Tri-State Generation & Transmission Association Nov 6, 2026
- RPM International Nov 6, 2026
- Fox Nov 6, 2026
- Enbridge Nov 6, 2026
- Federal Home Loan Bank of Des Moines Nov 5, 2026
- 1stdibs.com Nov 5, 2026
- TheRealReal Nov 5, 2026
- Algorhythm Holdings Nov 5, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.